Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1777 - 1784 of 12007 results

Could The RESTRICT ACT Create Jurisdictional Overlap With CFIUS?
March 9, 2023| News

Issues with USCIS online H-1B cap registration access
March 8, 2023| Blog| Viewpoint

Request for Good Faith Finding in New York Article 77 Proceedings May Not Waive Privilege
March 8, 2023| Blog| Viewpoint

Federal Trade Commission’s GoodRx Settlement: Not Just a $1.5 Million Penalty
March 8, 2023| Blog| Viewpoint

DOJ’s Criminal Division Announces Key Policy Updates Regarding Compensation, Compliance Programs, and Monitors
March 7, 2023| Blog| Viewpoint

SEC's ABS Proposal Could Spell Added Costs For Issuers
March 7, 2023| News

Federal Circuit Affirms Delisting of REMS System Patent from FDA Orange Book
March 6, 2023| Blog| Viewpoint

Access to Justice: A Conversation with Pro Bono Lawyer Susan M. Finegan
March 4, 2023| News
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|

Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|
